373 related articles for article (PubMed ID: 29243074)
21. Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?
Zakaria AS; Schwartz RN; Hodhod A; Couture F; Tholomier C; Shahine H; Negrean C; Nguyen DD; Zanaty M; Stolzenbach F; Karakiewicz PI; El-Hakim A; Zorn KC
World J Urol; 2021 Jun; 39(6):1853-1860. PubMed ID: 32696130
[TBL] [Abstract][Full Text] [Related]
22. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
[TBL] [Abstract][Full Text] [Related]
23. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
[TBL] [Abstract][Full Text] [Related]
24. When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database.
Abdollah F; Moschini M; Sood A; Sammon J; Dalela D; Hsu L; Beyer B; Haese A; Graefen M; Gandaglia G; Montorsi F; Briganti A; Menon M
J Endourol; 2016 Feb; 30(2):201-7. PubMed ID: 26415003
[TBL] [Abstract][Full Text] [Related]
25. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
26. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
[TBL] [Abstract][Full Text] [Related]
27. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
[TBL] [Abstract][Full Text] [Related]
28. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
29. Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study.
Kozal S; Peyronnet B; Cattarino S; Seisen T; Comperat E; Vaessen C; Mozer P; Renard-Penna R; Cussenot O; Rouprêt M; Drouin SJ
Urol Oncol; 2015 Jul; 33(7):330.e1-7. PubMed ID: 25998747
[TBL] [Abstract][Full Text] [Related]
30. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
[TBL] [Abstract][Full Text] [Related]
31. Comparison of robot-assisted and open retropubic radical prostatectomy for risk of biochemical progression in men with positive surgical margins.
Shapiro EY; Scarberry K; Patel T; Bergman A; Ahn JJ; Sahi N; RoyChoudhury A; Deutch I; McKiernan JM; Benson MC; Badani KK
J Endourol; 2014 Feb; 28(2):208-13. PubMed ID: 24044423
[TBL] [Abstract][Full Text] [Related]
32. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
33. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
34. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
[TBL] [Abstract][Full Text] [Related]
35. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Bissonette EA; Fulmer BR; Petroni GR; Moul JW; Theodorescu D
J Urol; 2001 Oct; 166(4):1328-31; discussion 1331-2. PubMed ID: 11547067
[TBL] [Abstract][Full Text] [Related]
36. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
37. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
38. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
Gandaglia G; De Lorenzis E; Novara G; Fossati N; De Groote R; Dovey Z; Suardi N; Montorsi F; Briganti A; Rocco B; Mottrie A
Eur Urol; 2017 Feb; 71(2):249-256. PubMed ID: 27209538
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
Ploussard G; Staerman F; Pierrevelcin J; Saad R; Beauval JB; Roupret M; Audenet F; Peyromaure M; Delongchamps NB; Vincendeau S; Fardoun T; Rigaud J; Villers A; Bastide C; Soulie M; Salomon L;
J Urol; 2013 Nov; 190(5):1750-6. PubMed ID: 23643600
[TBL] [Abstract][Full Text] [Related]
40. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
